Show simple item record

dc.contributor.authorPeiris-Pagès, Maria
dc.contributor.authorSmith, Duncan L
dc.contributor.authorGyőrffy, B
dc.contributor.authorSotgia, Federica
dc.contributor.authorLisanti, Michael P
dc.date.accessioned2016-01-06T10:46:37Zen
dc.date.available2016-01-06T10:46:37Zen
dc.date.issued2015-10en
dc.identifier.citationProteomic identification of prognostic tumour biomarkers, using chemotherapy-induced cancer-associated fibroblasts. 2015, 7 (10):816-38 Agingen
dc.identifier.issn1945-4589en
dc.identifier.pmid26539730en
dc.identifier.urihttp://hdl.handle.net/10541/592946en
dc.description.abstractCancer cells grow in highly complex stromal microenvironments, which through metabolic remodelling, catabolism, autophagy and inflammation nurture them and are able to facilitate metastasis and resistance to therapy. However, these changes in the metabolic profile of stromal cancer-associated fibroblasts and their impact on cancer initiation, progression and metastasis are not well-known. This is the first study to provide a comprehensive proteomic portrait of the azathioprine and taxol-induced catabolic state on human stromal fibroblasts, which comprises changes in the expression of metabolic enzymes, myofibroblastic differentiation markers, antioxidants, proteins involved in autophagy, senescence, vesicle trafficking and protein degradation, and inducers of inflammation. Interestingly, many of these features are major contributors to the aging process. A catabolic stroma signature, generated with proteins found differentially up-regulated in taxol-treated fibroblasts, strikingly correlates with recurrence, metastasis and poor patient survival in several solid malignancies. We therefore suggest the inhibition of the catabolic state in healthy cells as a novel approach to improve current chemotherapy efficacies and possibly avoid future carcinogenic processes.
dc.language.isoenen
dc.rightsArchived with thanks to Agingen
dc.titleProteomic identification of prognostic tumour biomarkers, using chemotherapy-induced cancer-associated fibroblasts.en
dc.typeArticleen
dc.contributor.departmentThe Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchesteren
dc.identifier.journalAgingen
html.description.abstractCancer cells grow in highly complex stromal microenvironments, which through metabolic remodelling, catabolism, autophagy and inflammation nurture them and are able to facilitate metastasis and resistance to therapy. However, these changes in the metabolic profile of stromal cancer-associated fibroblasts and their impact on cancer initiation, progression and metastasis are not well-known. This is the first study to provide a comprehensive proteomic portrait of the azathioprine and taxol-induced catabolic state on human stromal fibroblasts, which comprises changes in the expression of metabolic enzymes, myofibroblastic differentiation markers, antioxidants, proteins involved in autophagy, senescence, vesicle trafficking and protein degradation, and inducers of inflammation. Interestingly, many of these features are major contributors to the aging process. A catabolic stroma signature, generated with proteins found differentially up-regulated in taxol-treated fibroblasts, strikingly correlates with recurrence, metastasis and poor patient survival in several solid malignancies. We therefore suggest the inhibition of the catabolic state in healthy cells as a novel approach to improve current chemotherapy efficacies and possibly avoid future carcinogenic processes.


This item appears in the following Collection(s)

Show simple item record